



Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in

THE GASTRO CONVENTION

8th & 9th March, 2025 at Swosti Chilika Resort, Odisha.

"**The Gastro Convention**" convened in Chilika Resort, Odisha, orchestrated by the esteemed Weston Medical Education Foundation of India. This gathering aimed to amalgamate the expertise of Gastroenterologist and General Physicians from across India, fostering a dialogue on the intricacies of managing gastrointestinal diseases and its associated complications.

"During the CME, Weston Medical Education Foundation of India emphasized the essential role of such events in bridging the gap between cutting-edge research and everyday medical practice, ensuring wider access to knowledge for the benefit of all doctors and their patients."

Total Participants: 33 distinguished participants

EXPERTS

Faculties:

- Dr. Samir Kumar Hota
- Dr. Jayanta Sahoo
- Dr. Manoj Kumar Pani
- Dr. Sarat Panighrahi
- Dr. Amar Kumar Das
- Dr. Bibek Ranjan Jena



Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.
M: 9920154297 | W: www.wmefi.co.in

AGENDA

Day 1 – 8th March, 2025

Time: 2:00 p.m. to 9:00 p.m.

Topics	Speakers	Timings
Welcome Note		02:00 p.m. to 02:15 p.m.
Pantoprazole: Advancing the Management of Acid-Related Disorders	Dr. Samir Kumar Hota	02:15 p.m. to 03:00 p.m.
Modern Therapeutic Strategies for Acid-Related Disorders	Dr. Jayanta Sahoo	03:00 p.m. to 03:45 p.m.
Managing Helicobacter pylori Eradication with Pantoprazole	Dr. Manoj Kumar Pani	03:45 p.m. to 04:30 p.m.
Interactive Case Discussions on GI Disorders		04:30 p.m. to 05:15 p.m.
Tea Break		05:15 p.m. to 06:00 p.m.
Pantoprazole in High-Risk Patients: GERD with Complications	Dr. Bibek Ranjan Jena	06:00 p.m. to 06:45 p.m.
Emerging Data on Pantoprazole in Non-Erosive Reflux Disease (NERD)	Dr. Sarat Panigrahi	06:45 p.m. to 07:30 p.m.
Innovative Approaches to Gut Microbiome Research	Dr. Amar Kumar Das	07:30 p.m. to 08:15 p.m.
Discussion on the above Session		08:15 p.m. to 09:00 p.m.

Day 2 – 9th March, 2025

Time: 10:00 a.m. to 01:00 p.m.

Topics	Speakers	Timings
Recent Breakthroughs in the Management of Inflammatory Bowel Diseases	Dr. Bibek Ranjan Jena	10:00 a.m. to 10:45 a.m.
Advancements in Non-Invasive Diagnostic Tools	Dr. Manoj Kumar Pani	10:45 a.m. to 11:30 a.m.
Insights on Gastric Acid Suppression Beyond PPIs	Dr. Samir Kumar Hota	11:30 a.m. to 12:15 p.m.
Future Directions in the Management of Acid-Related Disorders	Dr. Sarat Panigrahi	12:15 p.m. to 12:45 p.m.
Discussion on the above Session		12:45 p.m. to 1:00 p.m.
Vote of Thanks		WMEFI



Summary of CME

Day 1:

❖ **Pantoprazole: Advancing the Management of Acid-Related Disorders: Dr. Samir Kumar Hota**

Dr. Hota discussed the pharmacological advantages of Pantoprazole in managing acid-related disorders such as GERD, peptic ulcers, and Zollinger-Ellison syndrome. He highlighted its superior acid suppression profile, prolonged duration of action, and meal-independent efficacy, making it a preferred choice for various patient populations. The session also covered recent clinical data demonstrating its effectiveness in achieving mucosal healing and symptom relief.

❖ **Modern Therapeutic Strategies for Acid-Related Disorders: Dr. Jayanta Sahoo**

Dr. Sahoo provided an in-depth review of the latest therapeutic advancements, including combination therapies, tailored treatment approaches, and novel drug formulations. He emphasized the importance of personalized medicine in optimizing treatment effectiveness and patient adherence. The discussion also included a comparative analysis of traditional PPIs versus emerging acid suppression therapies and their implications for clinical practice.

❖ **Managing Helicobacter pylori Eradication with Pantoprazole: Dr. Manoj Kumar Pani**

Dr. Pani explored the critical role of Pantoprazole in Helicobacter pylori eradication therapy. He discussed various treatment regimens, including triple and quadruple therapy, highlighting how Pantoprazole's superior acid suppression enhances bacterial eradication rates and reduces recurrence. The session also covered antibiotic resistance challenges and potential strategies to improve eradication success.

❖ **Interactive Case Discussions on GI Disorders:**

This session featured real-world case studies, allowing clinicians to engage in diagnostic problem-solving and evidence-based treatment decisions. Experts presented challenging cases involving refractory GERD, peptic ulcers, and acid-related complications. The discussions focused on differential diagnosis, optimal treatment strategies, and best practices for managing complex GI conditions.



❖ **Pantoprazole in High-Risk Patients: GERD with Complications: Dr. Bibek Ranjan Jena**

Dr. Jena addressed the management of GERD in high-risk patients, including those with Barrett's esophagus, esophageal strictures, and extra-esophageal manifestations. He emphasized Pantoprazole's role in minimizing disease progression and improving symptom control in complicated cases. The discussion also highlighted the need for long-term monitoring and lifestyle modifications in these patients.

❖ **Emerging Data on Pantoprazole in Non-Erosive Reflux Disease (NERD): Dr. Sarat Panighrahi**

Dr. Panighrahi presented new insights into the treatment of Non-Erosive Reflux Disease (NERD), including the efficacy of Pantoprazole in symptom relief and its advantages over other PPIs. The session covered recent clinical trials and real-world evidence supporting its use in patients with functional heartburn. Additionally, he discussed the role of acid sensitivity in NERD and how Pantoprazole addresses this aspect effectively.

❖ **Innovative Approaches to Gut Microbiome Research: Dr. Amar Kumar Das**

Dr. Das explored the interplay between gastric acid suppression and gut microbiome health. He discussed how PPIs like Pantoprazole may influence microbiome composition and potential strategies to mitigate dysbiosis-related complications. The session emphasized the importance of gut microbiota in overall GI health and the potential of microbiome-targeted therapies in gastroenterology.

❖ **Discussion on the Above Sessions:**

A moderated discussion allowed attendees to reflect on key insights from the day's sessions. Experts debated the clinical implications of recent data, shared experiences from daily practice, and addressed audience queries on optimizing Pantoprazole use in different patient populations.



Day 2:

❖ **Recent Breakthroughs in the Management of Inflammatory Bowel Diseases (IBD):
r. Bibek Ranjan Jena**

Dr. Jena reviewed advancements in IBD treatment, including novel biologics and small-molecule therapies for Crohn's disease and ulcerative colitis. He discussed the evolving role of acid suppression therapy in IBD patients, particularly in managing associated gastroesophageal symptoms and complications. The session highlighted the need for a multidisciplinary approach to optimizing long-term disease control.

❖ **Advancements in Non-Invasive Diagnostic Tools: Dr. Manoj Kumar Pani**

Dr. Pani presented innovations in non-invasive diagnostics, including pH monitoring, breath tests, and biomarker-based assessments. He emphasized how these tools enhance diagnostic accuracy, reduce the need for endoscopy, and improve patient care in acid-related disorders. The session also covered the role of AI-driven diagnostic techniques in gastroenterology.

❖ **Insights on Gastric Acid Suppression Beyond PPIs: Dr. Samir Kumar Hota**

Dr. Hota explored alternative approaches to acid suppression, including potassium-competitive acid blockers (P-CABs), mucosal protective agents, and novel drug delivery systems. The session focused on the limitations of long-term PPI use and the potential for emerging therapies to reshape the management of acid-related disorders. The discussion also addressed safety concerns associated with chronic acid suppression.

❖ **Future Directions in the Management of Acid-Related Disorders: Dr. Sarat Panighrahi**

Dr. Panighrahi provided a forward-looking discussion on upcoming research, emerging therapies, and evolving guidelines in acid-related disorder management. He highlighted the role of personalized medicine, technological innovations, and potential breakthroughs in acid suppression therapy. The session concluded with expert opinions on the next frontier in treating GERD and peptic ulcers.



Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in

DAY 1 & 2 Highlights:

- ❖ The symposium provided a comprehensive exploration of the evolving landscape of acid-related disorder management, with a strong focus on the role of Pantoprazole. Experts discussed its clinical advantages in GERD, NERD, and Helicobacter pylori eradication, along with its use in high-risk patients with complications.
 - ❖ Key discussions included modern therapeutic strategies, the impact of gut microbiome research, and emerging alternatives to PPIs. Additionally, recent breakthroughs in IBD management and non-invasive diagnostics were explored, emphasizing the integration of evidence-based medicine into clinical practice.
 - ❖ The event underscored the importance of combining clinical trial data with real-world applications to enhance patient outcomes, offering valuable insights into the future of gastric acid suppression therapy.
-
- **In the end of this CME, the Weston Medical Education Foundation of India extended, its sincere vote of thanks to the attending delegates and acknowledged the academic industry partners for their valuable support and contribution to the success of this event.**
-
- 1. La Renon Healthcare Pvt. Ltd. (Platinum Sponsor)**
 - 2. Aristo Pharmaceuticals Pvt. Ltd. (Gold Sponsor)**
 - 3. Samarth Life Sciences Pvt Ltd. (Silver Sponsor)**




Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.
M: 9920154297 | W: www.wmefi.co.in

Snapshots of Success

WELCOME DELEGATES





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in

REGISTRATION COUNTER



SESSIONS





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.
M: 9920154297 | W: www.wmefi.co.in





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in







Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in



SPONSORSHIP BRANDING





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in

PLATINUM SPONSOR



GOLD SPONSOR





Weston Medical Education Foundation of India

Office No:- 99,9th Floor, Kalpataru Avenue, Opp. ESIC Hospital, Kandivali (East) , Mumbai -400101.

M: 9920154297 | W: www.wmefi.co.in

SILVER SPONSOR

